Showing 6,021 - 6,040 results of 9,650 for search 'significant ((((gap decrease) OR (((we decrease) OR (greater decrease))))) OR (mean decrease))', query time: 0.41s Refine Results
  1. 6021

    Figure 4 from Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer Patients by Lauren Polyakov (21672045)

    Published 2025
    “…Data are presented as mean ± SEM. Ab, antibody; dex, dexamethasone; i.p., intraperitoneal; NS, not significant; αPD-L1, anti–PD-L1.…”
  2. 6022

    Application of yeast-based biocontrol agents against fruit spoilage moulds by Zukisani Gomomo (20853371)

    Published 2025
    “…The study concludes that the selected non-<i>Saccharomyces</i> yeasts hold significant potential as biological control agents against fruit spoilage moulds. …”
  3. 6023

    Western blot antibody information. by Shuailin Li (11907158)

    Published 2025
    “…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
  4. 6024

    Information on healthy and aniridia subjects. by Shuailin Li (11907158)

    Published 2025
    “…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
  5. 6025

    qPCR primers information. by Shuailin Li (11907158)

    Published 2025
    “…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
  6. 6026

    Table6_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  7. 6027

    Table4_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  8. 6028

    Supplementary Material for: Efficacy of penetrating canaloplasty versus trabeculectomy in patients with bilateral primary glaucoma: a self-control study by figshare admin karger (2628495)

    Published 2025
    “…Complete (without medication) and qualified success (with/without medication) were defined as IOP ≤21 mmHg and ≥20% IOP reduction. Results: Mean IOP decreased from 32.5±8.87mmHg on 2.3±1.43 medications at baseline to 14.6±4.41mmHg on 0.20±0.58 medications at 12 months in TRAB group (both p<0.0001) and from 30.0±9.61mmHg on 2.7±1.10 medications to 14.8±4.63mmHg on 0.12±0.44 medications in PCP group (both p<0.0001). …”
  9. 6029

    Table2_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  10. 6030

    Table8_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  11. 6031

    Datasheet1_Endovascular treatment of aortic coarctation using covered balloon-expandable stents—a systematic review and meta-analysis.pdf by Fei He (145896)

    Published 2024
    “…The estimated pooled procedural success rate was 100% [95% confidence interval (CI): 98%–100%, I2 = 0, P = 0.78]. Significant decreases in trans-coarctation PGs and SBP were observed. …”
  12. 6032

    Table5_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  13. 6033

    Table3_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  14. 6034

    Table1_Endovascular treatment of aortic coarctation using covered balloon-expandable stents—a systematic review and meta-analysis.pdf by Fei He (145896)

    Published 2024
    “…The estimated pooled procedural success rate was 100% [95% confidence interval (CI): 98%–100%, I2 = 0, P = 0.78]. Significant decreases in trans-coarctation PGs and SBP were observed. …”
  15. 6035

    Table7_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  16. 6036

    Table1_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.DOCX by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  17. 6037

    Table_2_Diffusion and functional MRI reveal microstructural and network connectivity impairment in adult-onset neuronal intranuclear inclusion disease.docx by Rui Zhu (305217)

    Published 2024
    “…Significantly decreased MK, RK, AK, KFA and fractional anisotropy (FA), and increased mean diffusivity (MD) values were observed in extensive white matter fiber tracts. …”
  18. 6038

    Data Sheet 1_Exploring long COVID in pediatric patients: clinical insights from a long COVID clinic.docx by Dina Kamel (22434430)

    Published 2025
    “…Overall symptom burden decreased significantly over time (p < 0.001). Vaccination status at baseline was not associated with difference in symptom duration on initial presentation (p = 0.4). …”
  19. 6039

    Data_Sheet_1_Diffusion and functional MRI reveal microstructural and network connectivity impairment in adult-onset neuronal intranuclear inclusion disease.docx by Rui Zhu (305217)

    Published 2024
    “…Significantly decreased MK, RK, AK, KFA and fractional anisotropy (FA), and increased mean diffusivity (MD) values were observed in extensive white matter fiber tracts. …”
  20. 6040

    Table_1_Diffusion and functional MRI reveal microstructural and network connectivity impairment in adult-onset neuronal intranuclear inclusion disease.docx by Rui Zhu (305217)

    Published 2024
    “…Significantly decreased MK, RK, AK, KFA and fractional anisotropy (FA), and increased mean diffusivity (MD) values were observed in extensive white matter fiber tracts. …”